IFFIm issues NOK 2B in Vaccine Bonds for COVID-19 vaccine development, backed by Norway.
Italy, the Netherlands, France and Spain renew support for IFFIm, together pledging US$ 926M.
A private placement sukuk raises US$ 50M in April. In July, IFFIm issues NOK600M vaccine bonds backed by Norway to fund CEPI’s development of new vacines.
Brazil becomes first Latin American donor country and second BRICS donor.
Cyrus Ardalan appointed as board chair.
IFFIm issues Vaccine Bonds in the international US dollar benchmark market, raising US$ 300M in a transaction jointly led by Citi, Crédit Agricole and Goldman Sachs International.
IFFIm’s return to international US benchmark raises US$ 500M in a transaction led by Citi, Deutsche Bank and J.P. Morgan. It is IFFIm’s second floating rate offer and fifth benchmark since 2006.
IFFIm donors make US$ 280M in additional pledges, and later strengthens profile in Islamic markets with second sukuk that raises US$ 200M. Meanwhile, global leaders gathered in Addis Ababa praise IFFIm's financial model.
The sukuk, an SRI that complies with Islamic law, raises US$ 500M and garners awards from The Financial Times and other outlets.
IFFIm cited as “SRI Innovation of the Decade” by mtn-i and raises US$ 700M in its first floating rate offer.
IFFIm’s 2008 Uridashi named among “25 most influential deals” by Euroweek, setting a trend for ethically themed bonds sold to retail investors in Japan. René Karsenti is appointed newboard chair.
while delivering 3x the value per dollar spent in a report by healthcare consulting firm HLSP which praised IFFIm’s model for its low-cost and efficiency. Meanwhile, Australia pledges AUD 250M over 20 years.
IFFIm issues AUD 400M, five-year bonds. Institutional investors show increasing support for IFFIm as a pioneering socially responsible investment in global health.
demonstrating its strong desire to engage the private sector. They are IFFIm’s eighth donor, pledging €60M over eight years.
IFFIm’s second Vaccine Bond sale secured US$ 223M from private investors in Japan, making it the largest South African rand-dominated bond in the Uridashi market to date.
South Africa contributes US$ 20M to IFFIm, which ends its first full year in operation having provided US$ 995M in health programme funding to 43 countries.
Funds raised from institutional investors accelerate funding that will enable Gavi to immunise more than 500 million children before 2015.
Six nations—the UK, France, Italy, Spain, Sweden and Norway, commit US$ 4B to support Gavi’s vaccine programmes.
The UK and France commit to launch an International Finance Facility for Immunisation (IFFIm), a pilot that would apply IFF principles to the immunisation sector.
The UK proposes a groundbreaking idea: an International Finance Facility, or IFF, to provide upfront funding to address critical needs in the developing world and work toward meeting the UN’s Millennium Development Goals by 2015.